| Factor Information | |
|---|---|
| Data ID | 3741 |
| Factor | the RV/FA ratio |
| Description | For patients with branch pulmonary stenosis, the RV/FA(right ventricle/femoral artery ratio) decreased from 0.5 to 0.39 (P<0.001). |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | We sought to determine the incidence of and risk factors for the development of restenosis and neointimal proliferation after endovascular stent implantation for congenital heart disease |
| p Value | <0.001 |
| Conclusion | Redilation or further dilation of endovascular stents for CHD is effective as late as 10 years. The risk of neointimal proliferation (1.8%) and restenosis (2%) is low and possibly avoidable. Awareness of specific risk factors and modification of the stent implantation technique, including avoidance of minimal stent overlap and sharp angulation of the stent to the vessel wall and avoidance of overdilation, have helped to reduce the incidence of restenosis. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 697 |
| CHD Type | isolated CHD |
| CHD Subtype | TOF/PA/CBPS/TR |
| Reference | |
|---|---|
| PMID | 11499747 |
| Year | 2001 |
| Title | Redilation of endovascular stents in congenital heart disease: factors implicated in the development of restenosis and neointimal proliferation. |
| Sample | ||
|---|---|---|
| Population | All | |
| Source | N/A | |
| Region | Houston, USA | |
| Method | N/A | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | stent implantation | |
| Group | patients of stent implantation with TOF/PA/CBPS/ASO(Treatment) | patients of stent redilation with TOF/PA/CBPS/ASO(Control) |
| Number | 88 | 88 |
| Age | N/A | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 0.5 | 0.39 |
